New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

The following is a summary of “Causal role of MiRNAs in chronic rhinosinusitis: mendelian randomization and validation study,” published in the April 2025 issue of Allergy, Asthma & Clinical ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.

Aclaris Therapeutics, Inc.’s ACRS share price has surged by 10.08%, which has investors questioning if this is right time to sell.

The FDA has approved Dupixent for chronic spontaneous urticaria in patients 12 and older unresponsive to antihistamines, ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

[99] Chronic rhinosinusitis with nasal polyps is characterized by eosinophilic inflammation and high IL-5 levels. The highest concentrations of IL-5 were found in NP tissue of subjects with ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

[3] CT scans in patients with chronic sinusitis will allow an adequate evaluation of anatomic abnormalities, including a deviated septum, nasal polyps, concha bullosa (air in the turbinates), as ...